Home Feed

Moderna's Noubar Afeyan on Coronavirus, Philanthropy and Immigration

Moderna's COVID-19 vaccine candidate is due to enter phase 3 clinical trial in July. The company's Chairman Noubar Afeyan, who is also the founder of Flagship Pioneering, is cautiously optimistic about the speedy approach to vaccine development. He talks to CivilNet's Syuzanna Petrosyan about Moderna, his philanthropic activities, and his path from an immigrant teenager fleeing civil war to a successful science innovator.

Newsletter

Subscribe to our newsletter and be the first to receive our weekly digests.

By subscribing, you agree to our Privacy Policy .

CivilNet content, photos, and videos may not be copied, downloaded, or republished on other platforms without proper attribution. Any partial use of CivilNet video requires prior knowledge and consent from CivilNet.

315 Arden Ave, Suite 30, Glendale, California 91203

+1(818)749-450 [email protected]

1 Northern Avenue, Office 30, Yerevan 0010, Armenia

+374(10)500-119

CIVILNET © 2011-2026. All rights reserved.

Developed by MATEMAT